Headlines

Thermo Fisher Scientific (TMO) CEO says pharma reshoring is going to be a tailwind in 2027 and 2028 for this industry; will be active in deploying advanced AI capabilities to drive additional cost

Newsquawk Staff ·

Thermo Fisher Scientific (TMO) CEO says pharma reshoring is going to be a tailwind in 2027 and 2028 for this industry; will be active in deploying advanced AI capabilities to drive additional cost.

What it means

The CEO of Thermo Fisher Scientific highlighted a future tailwind from pharma reshoring in 2027 and 2028, suggesting potential growth opportunities in the life sciences sector. Additionally, their focus on deploying advanced AI capabilities indicates a strategic push towards cost efficiency, which could enhance profitability in a competitive landscape. Investors might see this as a positive sign for longer-term prospects and operational robustness.

Related headlines